Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dingluo nasal drops is a Traditional Chinese Medicine (TCM) formulation developed by Dongzhimen Hospital, Beijing University of Chinese Medicine, for the acute treatment of migraine attacks. The drug is administered intranasally, a route intended to facilitate rapid absorption and potentially direct delivery to the central nervous system via the olfactory and trigeminal nerve pathways, thereby bypassing the blood-brain barrier. The formulation is based on the TCM therapeutic principle of extinguishing wind and stabilizing the collaterals to address the underlying pathology of vascular headaches. It is currently undergoing clinical evaluation in China to assess its efficacy in reducing pain intensity and associated symptoms during acute migraine episodes in adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dingluo nasal drops.